下载文档原格式
Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:HSF1A is a cell–permeable activator of heat shock transcription factor 1 (HSF1).IC50 & Target: HSF1[1]In Vitro: HSF1A protects cells from stress–induced apoptosis, binds TRiC subunits and inhibits TRiC activity without perturbation of ATP hydrolysis. Genetic inactivation or depletion of the TRiC complex results in human HSF1 activation and HSF1A inhibits the direct interaction between purified TRiC and HSF1 in vitro. Moreover, fluorescence anisotropy experiments using FITC coupled to HSF1A demonstrates that HSF1A–FITC binds to a purified Tcp1 subunit of TRiC with an affinity of approximately 600 nM. This is validated qualitatively via titration of purified Tcp1 into binding reactions containing 500 nM Biotin or HSF1A–Biotin [1]. Quantification bycounting the number of cell containing aggregates as a function of the total number of cells reveals that at HSF1A concentrations as low as 2 μM, a reduced number of aggregate–containing cells are observed. The fraction of cells containing aggregates continued to decrease in a dose–dependent manner such that pretreatment with 12 μM HSF1A resulta in ~20% of the cells exhibiting aggregates visible by fluorescence microscopy [2].In Vivo: HSF1A enhances HSF1 activity, stabilizes HSF1 expression and minimizes Doxorubicin (DOX)–induced cardiac damage. WKY rats are challenged with DOX (accumulated dose: 30 mg/kgw), and DOX combined with HSF1A (100 mg/kgw/day). Supplementation with HSF1A significantly elevates cardiac functions back to the levels of the control group. HSF1A has been shown to stimulate human HSF1 nuclear translocation, elevate protein chaperone expression and ameliorate protein misfolding and cell death in aneurodegenerative disease model. The echocardiographic results show that HSF1A also alleviates DOX–induced failures in cardiac function [3].PROTOCOL (Extracted from published papers and Only for reference)Kinase Assay:[1]Protein extracts are generated from mammalian, yeast and E. coli cultures using biotin–binding buffer (20 mM HEPES,5 mM MgCl 2, 1 mM EDTA, 100 mM KCl, 0.03% NP–40) supplemented with 1% Trition–X100 and protease inhibitors. Approximately 0.5mg of protein extract is incubated with 100 μM HSF1A–Biotin for 4 h at 4°C and HSF1A–Biotin associated proteins captured by with NeutrAvidin Agarose Resin. After washing in biotin binding buffer proteins are eluted using 50 μL biotin elution buffer (100 mM Tris,150 mM NaCl, 0.1 mM EDTA, 2 mM D–biotin), resolved on a 4–20% SDS–PAGE, and immunoblotted. For purified TRiC and Hsp70analyses, 5 nM protein is incubated in biotin–binding buffer+0.5% Triton X–100 with 100 μM biotin or 100 μM HSF1A–Biotin for 4 h at 4°C and captured with NeutrAvidin Resin. For NiNTA purified yeast Tcp1, different concentrations of Tcp1 0.5 μM, 1 mM, 2 mM, 3 mM and 4 mM in 25 mM Hepes pH 7.5, 150 mM NaCl are incubated with 0.5 μM Biotin or HSF1A–Biotin for 4 h at 4°C and captured with NeutrAvidin Resin [1].Cell Assay:[2]PC12 cells seeded into a 96–well plate (5×104 cells/well) are treated with increasing concentrations of HSF1A (2, 4, 8 andProduct Name:HSF1A Cat. No.:HY-103000CAS No.:1196723-93-9Molecular Formula:C21H19N3O2S2Molecular Weight:409.52Target:HSP Pathway:Cell Cycle/DNA Damage; Metabolic Enzyme/Protease Solubility:DMSO: ≥ 150 mg/mL12 μM) for 15 h, at which time httQ74–GFP expression is stimulated by incubation in the presence of 1 μg/mL Doxycycline for 5 d. Cell viability is assessed via the XTT viability assay[2].Animal Administration:[3]Rat[3]Ten–week–old Wistar Kyoto rats (WKY) are used. The rats are housed at a constant temperature (22°C) on a 12–h light/dark cycle with food and tap water. The animals are arranged into three groups: WKY rats (the control group), DOX rats and DOX rats treated with HSF1A. Each group contain five animals. The DOX group is injected with DOX (5 mg/kg) for 6 consecutive weeks intraperitoneal injection to achieve a cumulative dose of 30 mg/kg, which has been well documented to achieve cardiotoxicity. The small molecular HSF1 activator HSF1A (100 mg/kg/day) is injected intraperitoneally.References:[1]. Neef DW, et al. A direct regulatory interaction between chaperonin TRiC and stress–responsive transcription factor HSF1. Cell Rep. 2014 Nov 6;9(3):955–66.[2]. Neef DW, et al. Modulation of heat shock transcription factor 1 as a therapeutic target for small molecule intervention in neurodegenerative disease. PLoS Biol. 2010 Jan 19;8(1):e1000291.[3]. Huang CY, et al. Doxorubicin attenuates CHIP–guarded HSF1 nuclear translocation and protein stability to trigger IGF–IIR–dependent cardiomyocyte death. Cell Death Dis. 2016 Nov 3;7(11):e2455.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
碧云天生物技术/Beyotime Biotechnology订货热线：400-168-3301或800-8283301订货e-mail：******************技术咨询：*****************网址：碧云天网站微信公众号Cyclodextrin Glucanotransferase (Crude Enzyme)产品编号产品名称包装P3618-100ml Cyclodextrin Glucanotransferase (Crude Enzyme) 100mlP3618-1L Cyclodextrin Glucanotransferase (Crude Enzyme) 1L产品简介：Cyclodextrin Glucanotransferase，中文名为环糊精糖基转移酶，催化淀粉转移葡萄糖基生成环糊精。
本产品为大肠杆菌表达的环糊精糖基转移酶，并经简单纯化获得的可以确保达到一定酶活力的粗酶液。
由于本产品需新鲜制备，确认订购后约6个工作日才可以发货。
个别情况首次制备出现问题，发货时间会顺延。
本产品可以提供十公斤、百公斤乃至吨级的粗酶液，如有需求请联系碧云天。
In enzymology, a cyclomaltodextrin glucanotransferase is an enzyme that catalyzes the chemical reaction of cyclizing part of a 1,4-alpha-D-glucan molecule through the formation of a 1,4-alpha-D-glucosidic bond.This enzyme belongs to the family of glycosyltransferases, specifically the hexosyltransferases.This product with the indicated enzyme activity was briefly purified from engineered E.coli.产品详细信息见下表：About this productName Cyclodextrin Glucanotransferase (Crude Enzyme)；环糊精糖基转移酶(粗酶液)Application 催化淀粉转移葡萄糖基生成环糊精Appearance Clear to translucent yellow solutionEnzyme activity UndeterminedAbout this enzymeName Cyclodextrin Glucanotransferase；环糊精糖基转移酶CAS Number 9030-09-5EC Number 2.4.1.19Enzymatic Reaction Cyclizes part of a (1→4)-α-D-glucan chain by formation of a (1→4)-α-D-glucosidic bondSynonyms Bacillus macerans amylase; cyclodextrin glucanotransferase; α-cyclodextrin glucanotransferase; α-cyclodextrin glycosyltransferase; β-cyclodextrin glucanotransferase; β-cyclodextrin glycosyltransferase; γ-cyclodextrin glycosyltransferase; cyclodextrin glycosyltransferase; cyclomaltodextrin glucotransferase; cyclomaltodextrin glycosyltransferase; konchizaimu; α-1,4-glucan 4-glycosyltransferase, cyclizing; BMA; CGTase; neutral-cyclodextrin glycosyltransferase; 1,4-α-D-glucan 4-α-D-(1,4-α-D-glucano)-transferase (cyclizing)Systematic name (1→4)-α-D-glucan:(1→4)-α-D-glucan 4-α-D-[(1→4)-α-D-glucano]-transferase (cyclizing)Cofactor(s) -Application industry; synthesis; nutrition; pharmacology包装清单：产品编号产品名称包装P3618-100ml Cyclodextrin Glucanotransferase (Crude Enzyme) 100mlP3618-1L Cyclodextrin Glucanotransferase (Crude Enzyme) 1L－说明书1份保存条件：-20ºC或更低温度保存，至少1个月有效。
第43 卷第 2 期2024 年2 月Vol.43 No.2285~291分析测试学报FENXI CESHI XUEBAO（Journal of Instrumental Analysis）超高效液相色谱-三重四极杆质谱法测定化妆品中8种替丁类禁用药物张秋炎，梁维维，罗辉泰*，廖均涛，黄芳，吴惠勤（广东省科学院测试分析研究所（中国广州分析测试中心），广东省化学测量与应急检测技术重点实验室，广东省中药质量安全工程技术研究中心，广东广州510070）摘要：建立了同时测定5种不同基质类型化妆品中8种替丁类药物的超高效液相色谱-三重四极杆质谱法（UHPLC-MS/MS）。
不同基质类型化妆品样品经水-乙腈（2∶8，体积比）涡旋混匀、超声提取后过滤上机分析。
选用YMC-Triart C18色谱柱（100 mm×2.1 mm，3.0 μm），以0.2%甲酸溶液-乙腈为流动相进行梯度洗脱分离，质谱分析采用电喷雾正离子模式和多反应监测模式。
实验表明，8种替丁类药物在各自质量浓度范围内线性关系良好，相关系数（r2）为0.997 5~0.998 6，检出限为0.06~0.3 μg/L，定量下限为0.2~1.0 μg/L。
在3个不同加标水平下，水剂类、膏霜类、乳液类、凝胶类和粉剂类样品的平均回收率分别为80.7%~106%、90.1%~102%、82.6%~101%、82.0%~110%和86.6%~101%；相对标准偏差为0.70%~7.9%。
该法前处理过程简单高效，易操作，灵敏度高，适用于上述5种类型化妆品中8种替丁类药物的同时快速定性定量分析。
关键词：超高效液相色谱-三重四极杆质谱法；化妆品；抗组胺；替丁类药物中图分类号：O657.7；TQ658文献标识码：A 文章编号：1004-4957（2024）02-0285-07Determination of 8 Prohibited Tidine Drugs in Cosmetics by UltraHigh Performance Liquid Chromatography-Triple QuadrupoleMass SpectrometryZHANG Qiu-yan，LIANG Wei-wei，LUO Hui-tai*，LIAO Jun-tao，HUANG Fang，WU Hui-qin（Guangdong Provincial Engineering Research Center for Quality and Safety of Traditional Chinese Medicine，Guangdong Provincial Key Laboratory of Chemical Measurement and Emergency Test Technology，Institute of Analysis，Guangdong Academy of Sciences（China National Analytical Center，Guangzhou），Guangzhou 510070，China）Abstract：A new method for the simultaneous and rapid determination of 8 tidine drugs in 5 different matrix types of cosmetics by ultra high performance liquid chromatography-triple quadrupole mass spectrometry（UHPLC-MS/MS） was established. The different matrix cosmetic samples were dipersed with water-acetonitrile（2∶8，volume ratio） and ultrasonic extraction，and the filtrate was analyzed by UHPLC-MS/MS. A YMC-Triart C18 column（100 mm×2.1 mm，3.0 μm） was used as separation chromatographic column，with 0.2% formic acid aqueous solution and acetonitrile as mobile phases under gradient elution. Eight tidines drugs were analyzed in the positive mode using multiple reaction monitoring mode and electrospray ionization mass spectrometry. The results showed that the correla⁃tion coefficients for linear calibration curves were ranged of 0.997 5-0.998 6 in the corresponding concentration range. The limits of detection（LODs） of 8 tidine drugs were in the range of 0.06-0.3 μg/L，and the limits of quantitation（LOQs） were in the range of 0.2-1.0 μg/L. The average recover⁃ies of 8 tidine drugs from water aqua，cream，lotion，gel and powder samples at three different spiked levels ranged of 80.7%-106%，90.1%-102%，82.6%-101%，82.0%-110% and 86.6%-101%，re⁃spectively，with relative standard deviations ranged of 0.70%-7.9%. The established method is sim⁃ple，effective，easy to operate，high sensitive，and accurate，and is suitable for the determination of 8 tidine drugs in 5 different matrixes of cosmetics（including water aqua，cream，lotion，gel and收稿日期：2023－08－14；修回日期：2023－10－04基金项目：广东省科学院打造综合产业技术创新中心行动资金项目“高端医疗健康与高效生物转化关键技术研究及应用”（2022GDASZH-2022010110）∗通讯作者：罗辉泰，副研究员，研究方向：色谱-质谱分析技术应用，E-mail：luohuitai@doi：10.12452/j.fxcsxb.23081401第 43 卷分析测试学报powder samples ）.Key words ：UHPLC-MS/MS ；cosmetics ；antihistamine ；tidine drugs化妆品产业高质量发展的同时，其安全问题也日益引起消费者的重视。
粉防己碱的药理作用及临床应用研究进展孔晓旭1，2，左红艳1*，李杨1，2*［摘要］粉防己碱（tetrandrine，TET）是从防己科植物防己中提取出的一种双苄基异喹啉生物碱。
目前研究发现，TET作为粉防己植物中的重要活性成分之一，药理作用也较为广泛。
TET主要作用于机体的循环系统、呼吸系统及运动系统，具有抗肿瘤、抗心律失常、抗高血压、抗炎、抗硅肺及抗纤维化等多种药理作用，因此在临床上具有较高的应用价值。
本文就TET的药理作用机制、临床剂型及应用等方面的研究成果进行综述，以期为后续相关研究开展提供参考。
［关键词］粉防己碱；钙离子通道阻滞剂；药理作用；剂型；机制［中图分类号］R96；R285［文献标志码］A［文章编号］1674-0440（2020）07-0496-06 DOI：10.13220/ki.jipr.2020.07.002Pharmacological effects and clinical application of tetrandrine：research advancesKONG Xiao-xu1，2，ZUO Hong-yan1*，LI Yang1，2*（1.Institute of Radiation Medcine，Academy of Military Medical Sciences，Academy of Military Sciences，Beijing100850，China；2.Anhui Medical University，Hefei230032，China）［Abstract］Tetrandrine（TET）is a bisbenzyl isoquinoline alkaloid extracted from the plant Stephania tetrandra.TET is one of the important active ingredients of S.tetrandra，showing pharmacological effects mainly on the circulatory，respiratory and locomotor systems，such as the anti-inflammatory，anti-tumor，anti-arrhythmia，anti-hypertensive，anti-silicosis and fibrosis effect，and thus has a high clinical application value.This article reviews research achievements of the pharmacological effects，action mechanisms，dosage forms and clinical applications of TET，in order to provide reference for related research.［Key word］tetrandrine；calcium channel blocker；pharmacological action；dosage form；mechanism防己，又名汉防己、粉防己，是一种常用传统中药，主要产于中国浙江、广东、广西、福建等地。
EUROPEAN COMMISSIONDG Internal Market, Industry, Entrepreneurship and SMEsConsumer, Environmental and Health TechnologiesHealth technology and Cosmetics备注：中文翻译中的临床调查=临床研究，评估=评价、设备=器械、数据=资料MEDDEV 2.7/1 revision 4June 2016GUIDELINES ON MEDICAL DEVICES 医疗器械指南CLINICAL EVALUATION:A GUIDE FOR MANUFACTURERS AND NOTIFIED BODIES UNDER DIRECTIVES 93/42/EEC and 90/385/EECNoteThe present Guidelines are part of a set of Guidelines relating to questions of application of EC-Directives on medical Devices. They are legally not binding. The Guidelines have been carefully drafted through a process of intensive consultation of the various interested parties (competent authorities, Commission services, industries, other interested parties) during which intermediate drafts where circulated and comments were taken up in the document. Therefore, this document reflects positions taken by representatives of interest parties in the medical devices sector. These guidelines incorporate changes introduced by Directive 2007/47/EC amending Council Directive 90/385/EEC and Council Directive93/42/EEC.本指南为一系列与CE—医疗器械指令应用问题相关的指南中的一部分。
硫酸皮肤素差向异构酶(DSE)ELISA试剂盒说明书本试剂仅供研究使用标本：体液硫酸皮肤素差向异构酶(DSE)ELISA试剂盒说明书试验原理：BFGF试剂盒是固相夹心法酶联免疫吸附实验（ELISA）.已知BFGF浓度的标准品、未知浓度的样品加入微孔酶标板内进行检测。
先将BFGF和生物素标记的抗体同时温育。
人碱性成纤维细胞生长因子ELISA 检测试剂盒洗涤后，加入亲和素标记过的HRP。
再经过温育和洗涤，去除未结合的酶结合物，然后加入底物A、B，和酶结合物同时作用。
产生颜色。
颜色的深浅和样品中BFGF的浓度呈比例关系。
硫酸皮肤素差向异构酶(DSE)ELISA试剂盒说明书自备材料1．蒸馏水。
2．加样器：5ul、10ul、50ul、100ul、200、500ul、1000ul。
3．振荡器及磁力搅拌器等。
安全性1．避免直接接触终止液和底物A、B。
一旦接触到这些液体，请尽快用水冲洗。
2．实验中不要吃喝、抽烟或使用化妆品。
3．不要用嘴吸取试剂盒里的任何成份。
硫酸皮肤素差向异构酶(DSE)ELISA试剂盒说明书操作注意事项1．试剂应按标签储存，使用前恢复到室温。
稀稀过后的标准品应丢弃，不可保存。
2．实验中不用的板条应立即放回包装袋中，密封保存，以免变质。
3．不用的其它试剂应包装好或盖好。
不同批号的试剂不要混用。
保质前使用。
4．使用一次性的吸头以免交叉污染，吸取终止液和底物A、B液时，避免使用带金属部分的加样器。
5．使用干净的塑料容器配置洗涤液。
使用前充分混匀试剂盒里的各种成份及样品。
6．洗涤酶标板时应充分拍干，不要将吸水纸直接放入酶标反应孔中吸水。
7．底物A应挥发，避免长时间打开盖子。
底物B对光敏感，避免长时间暴露于光下。
避免用手接触，有毒。
实验完成后应立即读取OD值。
8．加入试剂的顺序应一致，以保证所有反应板孔温育的时间一样。
9．按照中标明的时间、加液的量及顺序进行温育操作。
硫酸皮肤素差向异构酶(DSE)ELISA试剂盒说明书样品收集、处理及保存方法1、血清-----操作过程中避免任何细胞刺激。
